to evaluate healthrelated quality of life of neuromyelitis optica spectrum disorders
to evaluate costs
to evaluate myelin oligodendrocyte glycoprotein antibodyassociated disease
in this multicenter crosssectional study data on consumption of nonmedical resources were assessed via patient questionnaires
in this multicenter crosssectional study data on consumption of medical resources were assessed via patient questionnaires
in this multicenter crosssectional study data on consumption of work ability were assessed via patient questionnaires
costs were analyzed in euros for 2018 from the societal perspective
healthrelated quality of life was captured by the euroqol group 5 dimension 5 level scale questionnaire
clinical data were retrieved from the neuromyelitis optica study group database
two hundred twelve patients were analyzed
the mean total annual per capita cost of illness accounted for 59574 euros
the most important cost drivers were indirect costs
the most important cost drivers were informal care costs
the most important cost drivers were drugs especially immunotherapeutics
costs showed a positive correlation with disease severity
the healthrelated quality of life revealed a negative correlation to disease severity
disease duration influenced healthrelated quality of life
neither antibody status influenced the total annual costs of life
neither antibody status influenced healthrelated quality of life
disease duration influenced the total annual costs of life
these german data from the era without approved preventive immunotherapies show enormous effects of the diseases on quality of life
these german data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs of life
an early therapy should be provided to preserve quality of life
an costeffective therapy should be provided to prevent longterm disability
an costeffective therapy should be provided to preserve quality of life
an early therapy should be provided to prevent longterm disability